We aim to develop a device that allows for stable and easy administration of vaccines to areas rich in immune cells, such as the skin.
- This is an intradermal (ID) device that can maintain equivalent activity even when the vaccine dosage is reduced compared to intramuscular (IM) or subcutaneous (SC) administration. - We are developing a method that aims to make the technically challenging intradermal administration simple and stable by just pressing the device against the skin like a stamp. - We are applying the technology of our company's resin-made lancet needle "Pinnix Light," which has an automatic needle tip retraction feature that prevents reuse after a single use, making it suitable for distributed formulations and avoiding needle-stick injuries. - In addition to vaccine applications, it is possible to improve pharmacokinetic properties through enhanced blood circulation duration for a wide range of pharmaceuticals, including antibody drugs.
Inquire About This Product
basic information
Our company aims to develop a dosing device that allows for easy and highly reproducible administration without the need for delicate adjustments to the needle tip angle, simply by pressing it like a stamp. Additionally, the traditional metal needles have posed a serious risk of secondary infections due to needlestick accidents after disposal. By adopting resin needles that utilize the technology of our developed lancet needle, PINNIX, we aim to eliminate this risk by allowing for immediate incineration after use, thus addressing the secondary infection risk associated with medical waste. Furthermore, since most of the housing, including the needle, is made of resin, it is cost-effective, and we aim to establish a supply system that allows for distribution in sterilized, individually packaged forms. Through this, we envision a future where vaccine-filled devices are distributed from medical institutions to households, enabling self-administration at home and dramatically promoting vaccine dissemination in developing countries.
Price range
P1
Delivery Time
P4
Applications/Examples of results
- Reduction in manufacturing costs per dose due to a decrease in vaccine dosage - Improvement of pharmacokinetic properties due to extended blood circulation time of biopharmaceuticals
Detailed information
-
Lightnix aims to address social issues surrounding vaccines and pursue international medical innovation for the prevention of infectious diseases worldwide through its unique vaccine delivery device inspired by the needle of a "mosquito."
catalog（1）
Download All Catalogs
Company information
Lightnix is a venture company established in 2002 with the aim of developing environmentally friendly medical devices. As a result of our research, we completed a plant-based resin lancet needle in 2012, receiving approval from the Ministry of Health and the FDA, and launched a lancet needle made entirely in Japan from the materials used. Through our unique technology that mimics mosquito needles, we successfully developed a low-invasive design that results in smaller wounds compared to traditional metal needles. Currently, we are also focusing on utilizing this technology to develop intradermal vaccine delivery devices.